Pharmacovigilance flat fee proposal on track; EMA changes expectations on management of ADRs from non-interventional studies
This article was originally published in SRA
Executive Summary
The European Commission has confirmed that it is on track to issue a revised pharmacovigilance fee proposal by the end of June1. Separately, the European Medicines Agency is inviting feedback on two draft pharmacovigilance guidelines2-4.